ArticleFrontiers in pharmacology2026
Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have substantially improved long-term oncologic outcomes in patients with advanced malignancies; however, ICI-related cardiovascular adverse events have emerged as a growing clinical challenge. Accumulating clinical evidence confirms that ICI treatment markedly increases the risk of atherosclerotic cardiovascular disease (ASCVD). Although cardiovascular toxicities secondary to ICIs are relatively infrequent, these complications carry severe and potentially fatal clinical consequences. Herein, we describe a rare case of acute non-ST-segment elevation myocardial infarction (NSTEMI) complicated by accelerated atherosclerosis potentially associated with ICI therapy in a middle-aged woman with advanced cervical squamous cell carcinoma harboring proficient mismatch repair (pMMR) status. Following successful coronary revascularization, the patient safely reinitiated immunotherapy and achieved long-term sustained tumor-free survival. Case presentation: A 39-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical squamous cell carcinoma, with comorbid type 2 diabetes mellitus and hypertension. She received first-line quadruple combination therapy comprising nab-paclitaxel, cisplatin, bevacizumab, and tislelizumab. Complete tumor response was achieved following six cycles of systemic treatment. Subsequent maintenance therapy combined with pelvic radiotherapy enabled sustained disease remission for more than 5 years. Approximately 2 years after transitioning to single-agent tislelizumab maintenance, the patient experienced an acute NSTEMI. Coronary angiography demonstrated severe multivessel coronary stenosis, and percutaneous coronary intervention (PCI) was performed successfully. After thorough multidisciplinary cardio-oncology evaluation, tislelizumab was safely reinitiated and continued until August 2024. At the most recent follow-up in June 2026, the patient maintained a persistent complete response with stable cardiac function. Conclusion: This case highlights that patients with advanced pMMR cervical cancer complicated by diabetes and hypertension can achieve durable complete remission exceeding 5 years with tislelizumab-based combination regimens. Furthermore, this case report also suggests that ICIs may be associated with cardiovascular events secondary to accelerated atherosclerosis, and demonstrates the clinical feasibility of safely resuming immune-checkpoint-inhibitor therapy following myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.